Company intelligence / Profile preview

AavantiBio

Cambridge, Massachusetts, United Statesocm.auburn.edu ↗

Ownership: Private
Development stage: Other

Overview

AavantiBio developed a pipeline of preclinical gene therapies, most notably an AAV-based candidate delivering full-length frataxin to treat both neurological and cardiac symptoms of Friedreich’s ataxia. The company also pursued programs in BAG3-mediated dilated cardiomyopathy. No clinical results have been reported as all programs remained preclinical prior to acquisition.

Therapeutic areas: NeurologyCardiovascular
Modalities: Gene therapyAAV-based gene therapy (Adeno-associated virus vector)
Industry: Biotech

Partnerships

Sarepta Therapeutics (investor/partner)University of Florida Powell Gene Therapy CenterCatalent Cell & Gene Therapy

Beyond the preview

Go deeper on AavantiBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AavantiBio.

Explore the full profile